Erasin
Erasin is a potent Erlotinib -resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; STAT
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/erasin.html
Purity
96.02
Solubility
DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N/N=C/C1=COC(C=CC(C(C)(C)C)=C2)=C2C1=O)C3=CC=CN=C3
Molecular Formula
C20H19N3O3
Molecular Weight
349.38
References & Citations
[1]Lis C, et al. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells. Sci Rep. 2017 Dec 12;7 (1) :17390.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
STAT1; STAT3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B810580-5G 5 g
(S)-(-)-1-tert-Butoxycarbonyl-3-aminopyrrolidine
Sign In for Pricing
View Details 
BNC680750-100 1x 100 µL
CD8 (C8/468 + C8/144B), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
